S100A8/A9在自身免疫性眼病中的作用:从发病机制到靶向治疗
本文综述S100A8/A9作为损伤相关分子模式在自身免疫性眼病发病中的作用。文章总结其生物学特征及其在自身免疫性葡萄膜炎、干燥综合征干眼病和甲状腺相关眼病中的促炎作用,强调其作为诊断生物标志物的潜力,并讨论靶向S100A8/A9的治疗策略。
要点
- S100A8/A9主要由中性粒细胞、单核细胞和树突状细胞表达,作为警报素驱动免疫反应。
- S100A8/A9在自身免疫性葡萄膜炎、干燥综合征干眼病和甲状腺相关眼病中上调并与发病相关。
- 靶向抑制S100A8/A9在该类眼病中具有治疗潜力,并可能作为诊断生物标志物。
核心结论
- S100A8/A9作为损伤相关分子模式在自身免疫性眼病发病中起关键作用,靶向干预具有诊断和治疗潜力。
研究设计与样本
- 本文为综述,总结S100A8/A9的生物学特征及其在三种自身免疫性眼病中的作用,并讨论靶向治疗策略。
主要发现
- S100A8/A9与受体结合后可驱动细胞因子、趋化因子和黏附因子产生,启动并放大免疫反应。
- S100A8/A9在多种自身免疫病中上调,在自身免疫性葡萄膜炎、干燥综合征干眼病和甲状腺相关眼病中与发病机制密切相关。
临床怎么用
- S100A8/A9可作为自身免疫性眼病的潜在诊断生物标志物,靶向S100A8/A9为治疗提供新方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The S100 proteins are a group of calcium-binding proteins that are widely expressed in vertebrates and participate in various biological and pathological processes, including cell proliferation, differentiation, inflammation, infection, and autoimmunity. S100A8 and S100A9, members of the S100 family that predominantly exist as heterodimers (S100A8/A9), are primarily localized in myeloid cells such as neutrophils, monocytes, and dendritic cells (DCs). Accumulating studies have identified S100A8/A9 as critical damage-associated molecular patterns (DAMPs) or alarmins. Upon engagement with their receptors, S100A8/A9 can drive the production of cytokines, chemokines, and adhesion factors, thereby initiating and amplifying immune responses. Current literature reports that S100A8/A9 is upregulated in various autoimmune diseases, and targeted inhibition of S100A8/A9 holds significant therapeutic potential for these diseases. Recently, emerging studies have demonstrated a close association between S100A8/A9 and the pathogenesis of autoimmune eye diseases. Elucidating the signaling pathways mediated by S100A8/A9 is critical for the prevention and treatment of these ocular disorders. Therefore, we here summarize the biological characteristics of S100A8/A9 and their roles in the onset and progression of three autoimmune eye diseases, including autoimmune uveitis, Sjögren's dry eye disease (SjDED), and thyroid-associated ophthalmopathy (TAO), with particular emphasis on their utility as diagnostic biomarkers. Furthermore, we discuss current therapeutic strategies targeting S100A8/A9 and propose promising future research directions for S100A8/A9 interventions in autoimmune eye diseases.
引用
- Zhang T, Hu J, Sun M, et al. The Role of S100A8/A9 in Autoimmune Eye Diseases: From Pathogenesis to Targeted Therapy. Invest Ophthalmol Vis Sci. 2026. PMID: 42770656. doi:10.1167/iovs.67.11.42
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。